Abstracts tagged "Biomarkers"

Abstract Number: 2649 • 2017 ACR/ARHP Annual Meeting
Anti-Suprabasin Antibody; A Novel Autoantibody May Contribute to the Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Kaname Ohyama², Kaori Furukawa¹, Osamu Higuchi³, Shunya Nakane⁴, Masataka Umeda¹, Tomohiro Koga¹, Takashi Igawa¹ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Course of Pharmaceutical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Clinical Research, Nagasaki Kawatana Medical Center, Nagasaki, Japan, ⁴Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Background/Purpose: Systemic lupus erythematosus (SLE), an autoimmune disorder characterized by the production of pathogenic autoantibodies and inflammatory mediators, involves multiple organ systems. Neuropsychiatric systemic lupus…
Abstract Number: 465 • 2017 ACR/ARHP Annual Meeting
Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials
Natasja Stæhr Gudman¹, Pernille Juhl¹, Christian S. Thudium², Peter Junker³, Anne Sofie Siebuhr⁴, Inger Byrjalsen¹, Morten Karsdal⁵ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular co-morbidity. The extra cellular matrix below the endothelial…
Abstract Number: 758 • 2017 ACR/ARHP Annual Meeting
Identification of Biomarkers Predictive of Pulmonary Arterial Hypertension in Systemic Sclerosis
Kathleen D. Kolstad¹, Tyson Holmes², Yael Rosenberg-Hasson², Andrew Sweatt³, Roham T. Zamanian⁴, Shufeng Li⁵, Virginia D. Steen⁶, Paul J. Utz⁷ and Lorinda Chung⁸, ¹Rheumatology, Stanford University Medical Center, Stanford, CA, ²Stanford University Medical Center, Stanford, CA, ³Medicine, Division of Pulmonary and Critical Care, Stanford University Medical Center, Stanford, CA, ⁴Stanford University Medical Center, Palo Alto, CA, ⁵Dermatology, Stanford University School of Medicine, Stanford, CA, ⁶Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁷Medicine, Stanford University School of Medicine, Stanford, CA, ⁸Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, immune system dysregulation, and fibrosis. Pulmonary arterial hypertension (PAH) affects approximately 10% of…
Abstract Number: 1281 • 2017 ACR/ARHP Annual Meeting
Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis
Katharine Moore^1,2, Marvin J. Fritzler³, Marisa S. Klein-Gitelman⁴, Ann M Reed⁵, Tzielan Lee⁶ and Anne Stevens^7,8, ¹Pediatrics, University of Colorado, Aurora, CO, ²Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ⁵Rheumatology, Duke University, Durham, NC, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷University of Washington, Department of Pediatrics, Seattle, WA, ⁸Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a severe and heterogeneous autoimmune vasculopathy. Pulmonary fibrosis is the highest independent predictor of mortality, yet currently there are…
Abstract Number: 1902 • 2017 ACR/ARHP Annual Meeting
A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Jon T. Giles¹, Cheilonda Johnson², Elana J. Bernstein³, Erika Darrah⁴, Felipe Andrade⁵ and Sonye K. Danoff⁶, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Columbia University, New York, NY, ⁴Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood. We explored the…
Abstract Number: 2669 • 2017 ACR/ARHP Annual Meeting
Microvascular Flow Assessed By Dynamic Optical Coherence Tomography: First Non-Invasive Quantitative Outcome Measure of Microvascular Disease in Systemic Sclerosis
Giuseppina Abignano^1,2, Alexandra Daniel^1,3, Lorraine Green^1,3, Sookhoe Eng^1,3, Paul Emery^1,3 and Francesco Del Galdo^1,3, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Rheumatology Institute of Lucania (IReL), Potenza, Italy, ³Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Virtual skin biopsy by Optical Coherence Tomography (OCT) has been proposed as quantitative outcome measure of fibrosis in Systemic Sclerosis (SSc). Dynamic OCT (D-OCT)…
Abstract Number: 466 • 2017 ACR/ARHP Annual Meeting
Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Martin Pelletier¹, Paul R. Fortin^1,2, Marie-Pier Longchamps¹, Geneviève Parent¹, Hadrien Benk-Fortin¹, Anne-Sophie Julien³, Nathalie Amiable¹, Emmanuelle Rollet-Labelle¹, Laetitia Michou², Louis Bessette² and Philippe A. Tessier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ³Clinical Research Platform, CHU de Québec-Université Laval Research Center, Québec, QC, Canada
Background/Purpose: Methotrexate (MTX) is the first line treatment for patients with rheumatoid arthritis (RA). For over 30% of patients, MTX fails to diminish DAS28 score…
Abstract Number: 771 • 2017 ACR/ARHP Annual Meeting
Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis
Pernille Juhl¹, Mette Mogensen², Line Iversen², Tonny Karlsmark², Morten Karsdal³, Anne-C. Bay-Jensen⁴ and Anne Sofie Siebuhr⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, Herlev, Denmark
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, autoimmune disease characterized by immune dysregulation, vasculopathy and excessive fibrosis of the skin and internal organs. Fibrosis is…
Abstract Number: 1322 • 2017 ACR/ARHP Annual Meeting
Tissue Folate Dysregulation Is Associated with Disease Activity and Methotrexate Response in Collagen-Induced Arthritis
Leon van Haandel¹, Rakesh Singh², Paul Kiptoo³, Teruna Siahaan³, Mara L Becker⁴ and Ryan Funk⁵, ¹2401 Gillham Road, Children's Mercy, Kansas City, MO, ²Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Methotrexate (MTX) is an anti-metabolite inhibitor of folate-dependent biochemical pathways and is effective in reducing disease activity in autoimmune arthritis. This work seeks to…
Abstract Number: 1918 • 2017 ACR/ARHP Annual Meeting
Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Martin Schmidt⁵, Robin Bruchas⁶, Nick Staten⁶, Paul Olson⁶, Chad Stiening⁶ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., St. Louis, MO, ⁶Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 2688 • 2017 ACR/ARHP Annual Meeting
Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Anne Sofie Siebuhr¹, Satoshi Kubo², Pernille Juhl³, K Nakano⁴, S Nakayamada⁵, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Yoshiya Tanaka⁸, ¹the first department of internal medicine, University of occupational and environmental health, Fukuoka, Japan, ²The first department of internal medicine, University of Occupational en environmental Health, Fukuoka, Japan, ³Nordic Bioscience, Herlev, Denmark, ⁴the first department of internal medicin, University of occupational and environmental health, fukuoka, Japan, ⁵The first department of internal medicine, University of Occupational and environmental Health, fukuoka, Japan, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biomarkers that can monitor the fibrotic burden will aid in trial enrichment and personalized health care in SSc. SSc is associated with internal organ…
Abstract Number: 50 • 2017 ACR/ARHP Annual Meeting
Quality Controls Monitoring As Indicator of Stability in Bone and Cartilage Turnover Markers for Clinical Trials
Yannick Lhoste, Vanessa Di Cataldo, Philippe Vergnaud and Tanja Schubert, Bioclinica Lab, LYON, France
Background/Purpose: Protein biomarkers are widely used in clinical studies to assess drug efficacy, such as bone and cartilage turnover markers in osteoarthritis or rheumatoid arthritis…
Abstract Number: 489 • 2017 ACR/ARHP Annual Meeting
Endotypic Clustering of Rheumatoid Arthritis Patients through the Use of Tissue Specific Serum Biomarkers Identifies Structural Progressors
Joseph Patrick Michele Blair¹, Cecilie Liv Bager¹, Line Mærsk Staunstrup¹, Henning Bay Nielsen¹, Morten Karsdal² and Anne-C. Bay-Jensen³, ¹ProScion, Herlev, Denmark, ²Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Treatment of RA patients is guided by measures of disease activity such as DAS28, best practice recommendation, and less often by a treat-to-target approach.…
Abstract Number: 782 • 2017 ACR/ARHP Annual Meeting
Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen, Marjolein Hoekstra, Johan Bijzet, Wayel H. Abdulahad, Annemieke M.H. Boots and Elisabeth Brouwer, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: GCA and PMR are closely related inflammatory diseases. The diagnostic criteria of both disorders depend on a combination of clinical features and elevated ESR…
Abstract Number: 1365 • 2017 ACR/ARHP Annual Meeting
Correlation of the Multi-Biomarker Disease Activity Score with Composite Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis
Tate Johnson¹, Kyle A. Register², Cynthia Schmidt³, James R. O'Dell⁴, Ted R. Mikuls⁵, Kaleb Michaud¹ and Bryant R. England⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ³McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The regular assessment of disease activity is necessary to implement a treat-to-target management approach in RA. The Multi-Biomarker Disease Activity (MBDA) Score is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].